StudyID,Drug_Name,Sponsor_Type,COVID_Impact,No_Competing_Trial,No_SOC,CRO,CRO_Oper,CRO_Stat,CRO_DM,RBM
NCT02039674,Pembrolizumab; Paclitaxel; Carboplatin; Bevacizumab; Pemetrexed; Ipilimumab; Erlotinib; Gefitinib,Industry,,,,,,,,
